GlassScriptPhysician profile
Tammy Guffey
NPI 1649949645
$1,742.92
in general payments reported to CMS, 2019-2025
22 companies · $332 in 2025
The $332 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $55.91 · 2022: $231 · 2023: $492 · 2024: $632 · 2025: $332.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,456.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,456.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $460.71 | 2021-2025 | Tezspire, Fasenra, Airsupra |
| Genzyme Corporation | $273.08 | 2022-2025 | |
| Glaxosmithkline, LLC. | $183.97 | 2022-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Regeneron Healthcare Solutions, INC. | $126.90 | 2023-2025 | Dupixent |
| Amgen INC. | $118.57 | 2021-2025 | Tezspire |
| Csl Behring | $77.08 | 2024-2025 | Haegarda, Andembry |
| Genentech USA, INC. | $74.35 | 2021-2024 | Xolair |
| Pfizer INC. | $52.38 | 2022-2023 | |
| Leo Pharma INC. | $51.05 | 2024 | Adbry |
| Optinose US, INC. | $42.20 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.90 | 2022 | |
| Kaleo, INC. | $37.08 | 2023 | Auvi-Q |
| Teva Pharmaceuticals USA, INC. | $35.64 | 2022 | |
| Verona Pharma, INC. | $25.67 | 2025 | Ohtuvayre |
| Octapharma USA, INC. | $23.79 | 2025 | Panzyga |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $23.32 | 2025 | |
| Galderma Laboratories, L.P. | $21.93 | 2025 | Nemluvio |
| Lilly USA, LLC | $20.41 | 2025 | Ebglyss |
| Biohaven Pharmaceutical Holding Company LTD. | $15.01 | 2022 | |
| Ionis Pharmaceuticals, INC. | $14.94 | 2025 | |
| Ars Pharmaceuticals Operations, INC. | $14.90 | 2025 | Neffy |
| Biodelivery Sciences International, INC. | $12.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tammy Guffey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.